Literature DB >> 23403235

Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population.

Praveen Kumar Jaiswal1, Vibha Singh, Priyanka Srivastava, Rama Devi Mittal.   

Abstract

IL-12 and IL-18 are immunomodulatory cytokines that play important roles in host immune response against cancers. Variation in DNA sequence in gene promoter may lead to altered IL-18 production and/or activity, and hence can modulate an individual's susceptibility to BC. To test this hypothesis, we investigated the relationship of IL-18 gene promoter -137 G/C and -607C/A polymorphisms and IL12 (-16974) A/C with the risk of BC in North Indian population. Polymorphisms in IL-18 and IL-12 genes were analyzed in 200 BC patients and 200 age, ethnicity and sex-matched controls, using restriction fragment length polymorphism-polymerase chain reaction (PCR-RFLP) and amplification refractory mutation specific-polymerase chain reaction (ARMS) method. The concentrations of IL-18 in serum were determined by ELISA. Significant association was observed with IL18 (-137) G/C heterozygous genotype (GC) with 1.96 folds risk of BC as well at C allele carrier and variant C allele having 2 fold and 1.6 fold risk for BC respectively. IL18 (-607) C/A, heterozygous CA genotype also showed a high risk (OR=1.59) for BC. While IL12 (-16974) A/C heterozygote genotype and C allele carrier demonstrated reduced risk of BC. Hetero genotype of IL18 (-137) G/C was associated with risk of recurrence (HR=2.35) in superficial BC patients receiving BCG treatment thus showing least survival. The distributions of IL-18 gene haplotypes were not significantly different between patients and controls. Serum IL-18 levels were significantly higher in BC patients than in the healthy subjects (p=0.025). Serum IL-18 levels was also significantly associated with IL18 (-137) G/C in heterozygous genotype (GC) (p=0.048). Our results suggest that IL-18 gene polymorphism contributes to bladder cancer risk whereas IL-12 is protective. A relation between IL18 (-137) G/C in heterozygous genotype with elevated IL-18 serum level and bladder cancer risk has been registered in the present study.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403235     DOI: 10.1016/j.gene.2013.01.025

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  19 in total

1.  Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.

Authors:  S Bank; P S Andersen; J Burisch; N Pedersen; S Roug; J Galsgaard; S Y Turino; J B Brodersen; S Rashid; B K Rasmussen; S Avlund; T B Olesen; H J Hoffmann; B A Nexø; J Sode; U Vogel; V Andersen
Journal:  Pharmacogenomics J       Date:  2017-01-31       Impact factor: 3.550

2.  The -137G>C polymorphism in interleukin-18 promoter region and cancer risk: evidence from a meta-analysis of 21 studies.

Authors:  Tie-Jun Liang; Hui Ma; Cong-Xiao Wang; Yin-Rong Liu; Xing-Guo Wang
Journal:  Tumour Biol       Date:  2013-06-22

3.  Association of interleukin-18 gene promoter -607 C>A and -137G>C polymorphisms with cancer risk: a meta-analysis of 26 studies.

Authors:  Xin Yang; Man-Tang Qiu; Jing-Wen Hu; Feng Jiang; Ming Li; Jie Wang; Qin Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

4.  Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro.

Authors:  Xiaoyi Liu; Jianxia Hu; Suyuan Sun; Funian Li; Weihong Cao; Y U Wang; Zhongliang Ma; Zhigang Yu
Journal:  Exp Ther Med       Date:  2015-02-11       Impact factor: 2.447

5.  The -137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients.

Authors:  Serap Yalçın; Pelin Mutlu; Türker Çetin; Meral Sarper; Gökhan Özgür; Ferit Avcu
Journal:  Turk J Haematol       Date:  2014-05-21       Impact factor: 1.831

6.  Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India.

Authors:  Prithvi Kumar Singh; Mohd Kaleem Ahmad; Vijay Kumar; Syed Rizwan Hussain; Rajni Gupta; Amita Jain; Abbas Ali Mahdi; Jaishri Bogra; Girish Chandra
Journal:  Tumour Biol       Date:  2014-11-15

7.  The -607C/A polymorphisms in interleukin-18 gene promoter contributes to cancer risk: evidence from a meta-analysis of 22 case-control studies.

Authors:  Ming Wang; Xiao-Yang Zhu; Liang Wang; Yu Lin
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

8.  Association between IL-18 polymorphisms, serum levels, and HBV-related hepatocellular carcinoma in a Chinese population: a retrospective case-control study.

Authors:  Jingui Bao; Yu Lu; Yan Deng; Chengzhi Rong; Yanqiong Liu; Xiuli Huang; Liuying Song; Shan Li; Xue Qin
Journal:  Cancer Cell Int       Date:  2015-07-25       Impact factor: 5.722

9.  Impact of interleukin-18 polymorphisms -607A/C and -137G/C on oral cancer occurrence and clinical progression.

Authors:  Hsiu-Ting Tsai; Chung-Han Hsin; Yi-Hsien Hsieh; Chih-Hsin Tang; Shun-Fa Yang; Chiao-Wen Lin; Mu-Kuan Chen
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

10.  Elevation of Interleukin-18 Correlates With Cardiovascular, Cerebrovascular, and Peripheral Vascular Events: A Cohort Study of Hemodialysis Patients.

Authors:  Chih-Hsiang Chang; Pei-Chun Fan; Chan-Yu Lin; Chia-Hung Yang; Yi-Ting Chen; Su-Wei Chang; Huang-Yu Yang; Chang-Chyi Jenq; Cheng-Chieh Hung; Chih-Wei Yang; Yung-Chang Chen
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.